Skip to main content

Table 1 Regimens, Duration, and Efficacy for Four Treatment Scenarios Modeled

From: Short-term budget affordability of hepatitis C treatments for state Medicaid programs

  Baseline Remove Sobriety Restrictions Treat Early Remove Access Restrictions
North Carolina F2+, Treat 6%, no PWIDs F2+, Treat 6%, Treat PWIDs F0+, Treat 8%, No PWIDs F0+, Treat 8%, Treat PWIDs
Oregon F3+, Treat 10%, no PWIDs F3+, Treat 10%, Treat PWIDs F0+, Treat 13%, No PWIDs F0+, Treat 13%, Treat PWIDs
Wisconsin F3+, Treat 18%, no PWIDs F3+, Treat 18%, Treat PWIDs F0+, Treat 24%, No PWIDs F0+, Treat 24%, Treat PWIDs
Drugs used sofosbuvir + velpatasvir for 12 weeks
SVR by disease stage F0-F3 F4, DC, HCC F0-F3 F4, DC, HCC F0-F3 F4, DC, HCC F0-F3 F4, DC, HCC
Genotype 1 At Risk 0.98 1.00 Same as Baseline
PWID 0.98 1.00 Same as Baseline
HIV+/MSM 0.96 0.96 Same as Baseline
Genotype 2 At Risk 0.99 1.00 Same as Baseline
PWID 0.99 1.00 Same as Baseline
HIV+/MSM 1.00 1.00 Same as Baseline
Genotype 3 At Risk 0.97 0.92 Same as Baseline
PWID 0.97 0.92 Same as Baseline
HIV+/MSM 0.92 0.91 Same as Baseline